TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Virtual Ward to Reduce Readmissions After Hospital Discharge
Brief Summary: The purpose of this study is to see whether a Virtual Ward reduces readmissions after hospital discharge.


Options:
A: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Virtual Ward; Type: EXPERIMENTAL; Interventions: Other: Virtual Ward | Intervention Type: OTHER; Name: Virtual Ward; Assigned to Arm(s): Virtual Ward | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Facilitator-Based intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Facilitator-Based intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana
Brief Summary: This study is designed to test the hypothesis that the intramuscular administration of 10 IU of oxytocin in Uniject™ during the third stage of labor by a Community Health Officer (CHO) at home births in Ghana will reduce the risk of postpartum hemorrhage by 50 percent relative to home births attended by the same type of provider who does not provide a uterotonic drug.


Options:
A: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
C: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin
D: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana
Brief Summary: This study is designed to test the hypothesis that the intramuscular administration of 10 IU of oxytocin in Uniject™ during the third stage of labor by a Community Health Officer (CHO) at home births in Ghana will reduce the risk of postpartum hemorrhage by 50 percent relative to home births attended by the same type of provider who does not provide a uterotonic drug.


Options:
A: Arm Label: Saline group; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Saline group
B: Arm Label: Short infusion; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin Short-infusion | Arm Label: Bolus application; Type: OTHER; Interventions: Drug: Carbetocin Bolus application | Intervention Type: DRUG; Name: Carbetocin Short-infusion; Assigned to Arm(s): Short infusion | Intervention Type: DRUG; Name: Carbetocin Bolus application; Assigned to Arm(s): Bolus application
C: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana
Brief Summary: This study is designed to test the hypothesis that the intramuscular administration of 10 IU of oxytocin in Uniject™ during the third stage of labor by a Community Health Officer (CHO) at home births in Ghana will reduce the risk of postpartum hemorrhage by 50 percent relative to home births attended by the same type of provider who does not provide a uterotonic drug.


Options:
A: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
B: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic Acid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hygienists Internet Tobacco Cessation Study (HiQuit)
Brief Summary: Our overall goal is to advance science related to using the Internet in health services delivery, and specifically smoking cessation by targeting dental hygienists. Our proposed intervention is the first Internet-delivered intervention to target the dental microsystem for smoking cessation-providing access to hygienists and patients.


Options:
A: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Smoking Cessation Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone Quitline Smoking Cessation Program | Intervention Type: BEHAVIORAL; Name: Telemedicine Smoking Cessation Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Telephone Quitline Smoking Cessation Program; Assigned to Arm(s): 2
C: Arm Label: Message Tone; Type: EXPERIMENTAL; Interventions: Behavioral: Message Tone | Arm Label: Testimonials; Type: EXPERIMENTAL; Interventions: Behavioral: Testimonials | Arm Label: Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Navigation | Arm Label: Proactive Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Proactive Outreach | Intervention Type: BEHAVIORAL; Name: Message Tone; Assigned to Arm(s): Message Tone | Intervention Type: BEHAVIORAL; Name: Navigation; Assigned to Arm(s): Navigation | Intervention Type: BEHAVIORAL; Name: Proactive Outreach; Assigned to Arm(s): Proactive Outreach | Intervention Type: BEHAVIORAL; Name: Testimonials; Assigned to Arm(s): Testimonials
D: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hygienists Internet Tobacco Cessation Study (HiQuit)
Brief Summary: Our overall goal is to advance science related to using the Internet in health services delivery, and specifically smoking cessation by targeting dental hygienists. Our proposed intervention is the first Internet-delivered intervention to target the dental microsystem for smoking cessation-providing access to hygienists and patients.


Options:
A: Arm Label: Lifestyle counseling; Type: OTHER; Interventions: Behavioral: Brief intervention | Intervention Type: BEHAVIORAL; Name: Brief intervention; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals
C: Arm Label: 1 Nix Individual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nix Individual | Arm Label: 2 Fimpa dig fri; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fimpa dig fri | Intervention Type: BEHAVIORAL; Name: Nix Individual; Assigned to Arm(s): 1 Nix Individual | Intervention Type: BEHAVIORAL; Name: Fimpa dig fri; Assigned to Arm(s): 2 Fimpa dig fri
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMOKELESS TOBACCO AWARENESS PROGRAM | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMOKELESS TOBACCO AWARENESS PROGRAM; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hygienists Internet Tobacco Cessation Study (HiQuit)
Brief Summary: Our overall goal is to advance science related to using the Internet in health services delivery, and specifically smoking cessation by targeting dental hygienists. Our proposed intervention is the first Internet-delivered intervention to target the dental microsystem for smoking cessation-providing access to hygienists and patients.


Options:
A: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
B: Arm Label: Electronic Referrals; Type: EXPERIMENTAL; Interventions: Other: Electronic Referral | Arm Label: Routine Referral; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic Referral; Assigned to Arm(s): Electronic Referrals
C: Arm Label: SAMe 800; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: SAMe 1600; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 800 | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 1600 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Brief Summary: To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.


Options:
A: Arm Label: Savolitinib; Type: EXPERIMENTAL; Interventions: Drug: Savolitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Savolitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
C: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Brief Summary: To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.


Options:
A: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
D: Arm Label: Cediranib (AZD2171) Treatment; Type: EXPERIMENTAL; Interventions: Drug: AZD2171 | Intervention Type: DRUG; Name: AZD2171; Assigned to Arm(s): Cediranib (AZD2171) Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced "Brain Fog."
Brief Summary: Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.


Options:
A: Arm Label: Patients taking the drug Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Patients taking the placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Patients taking the drug Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Patients taking the placebo
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
C: Arm Label: Imipramine treatment; Type: EXPERIMENTAL; Interventions: Drug: Imipramine treatment | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Imipramine treatment; Assigned to Arm(s): Imipramine treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Amiloride; Type: EXPERIMENTAL; Interventions: Drug: Amiloride | Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Amiloride | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced "Brain Fog."
Brief Summary: Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
C: Arm Label: Patients taking the drug Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Patients taking the placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Patients taking the drug Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Patients taking the placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: Objective: Chronic obstructive pulmonary disease (COPD) is a disease with significant morbidity and incurs heavy utilization of healthcare resources. The direct cost of hospital admissions related to COPD is the single largest source of expenditure in the public hospital system. This study aims to assess whether a comprehensive care programme can decrease the rate of hospital admissions for COPD patients.


Options:
A: Arm Label: comprehensive care programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive care programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive care programme; Assigned to Arm(s): comprehensive care programme
B: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: with mobile phone assistance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile-phone-based Home Exercise Training Program, Behavioral: Home Exercise Training Program | Arm Label: with free walk; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Home Exercise Training Program | Intervention Type: BEHAVIORAL; Name: Mobile-phone-based Home Exercise Training Program; Assigned to Arm(s): with mobile phone assistance | Intervention Type: BEHAVIORAL; Name: Home Exercise Training Program; Assigned to Arm(s): with free walk, with mobile phone assistance
D: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES

Answer: A